An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2018
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2018 Planned primary completion date changed from 31 Dec 2018 to 26 Nov 2018.
- 26 Jul 2018 Planned End Date changed from 19 Dec 2019 to 19 Jan 2019.